Q&A: Page 4

Exclusive interviews with industry leaders

  • Mayank Anand, vice president and global head of data strategy and management, GSK
    Image attribution tooltip
    Permission granted by GSK
    Image attribution tooltip

    This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

    The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.

    Michael Gibney • March 23, 2023
  • Babson Diagnostics
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Image attribution tooltip

    Babson aims to shed Theranos curse with new blood testing tech

    Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

    Kelly Bilodeau • March 13, 2023
  • Murray Aitken IQVIA Institute
    Image attribution tooltip
    Permission granted by Murray Aitken/IQVIA Institute
    Image attribution tooltip

    IQVIA’s OG of data analytics on the latest clinical trial trends

    IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

    Taren Grom • March 10, 2023
  • Cooked vegetables in black plastic containers
    Image attribution tooltip
    Permission granted by Faeth
    Image attribution tooltip

    While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

    The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

    Karissa Waddick • March 9, 2023
  • Cell therapy DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The ‘recovering academic’ leading Allogene to the next stage of cell therapy

    Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

    Michael Gibney • March 2, 2023
  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

    With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

    Taren Grom • March 2, 2023
  • Faby Malik Cytokinetics
    Image attribution tooltip
    Permission granted by Dr. Faby Malik, Cytokinetics
    Image attribution tooltip

    Cytokinetics looks to muscle into the cardiovascular market

    With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

    Taren Grom • Feb. 24, 2023
  • patient care
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why patient care is a public affair

    The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

    Taren Grom • Feb. 23, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

    Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

    Taren Grom • Feb. 17, 2023
  • Cancer antibodies
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

    The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

    Michael Gibney • Feb. 16, 2023
  • Will Chou headshot
    Image attribution tooltip
    Permission granted by Dr. William Chou, Passage Bio
    Image attribution tooltip

    Managing for resilience: Passage’s ups and downs in gene therapy

    After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

    Meagan Parrish • Feb. 15, 2023
  • Professional headshot of Brian Fox
    Image attribution tooltip
    Permission granted by Klick Group
    Image attribution tooltip

    Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

    Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

    Karissa Waddick • Feb. 13, 2023
  • Kinnari Patel Rocket Pharmaceuticals
    Image attribution tooltip
    Permission granted by Kinnari Patel Rocket Pharmaceuticals
    Image attribution tooltip

    Rocket Pharmaceuticals is ready for liftoff in the rare disease space

    With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

    Taren Grom • Feb. 10, 2023
  • Victoria Richon
    Image attribution tooltip
    Permission granted by Entact Bio
    Image attribution tooltip

    Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

    Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

    Kelly Bilodeau • Feb. 6, 2023
  • Jill Milne Astria Therapeutics
    Image attribution tooltip
    Permission granted by Jill Milne, Astria Therapeutics
    Image attribution tooltip

    Astria Therapeutics’ edge in an ultra-rare disease

    With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

    Taren Grom • Feb. 1, 2023
  • Marc de Garidel, CEO, CinCor
    Image attribution tooltip
    Permission granted by CinCor
    Image attribution tooltip

    This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

    With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

    Michael Gibney • Jan. 31, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    Meagan Parrish • Jan. 26, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    Karissa Waddick • Jan. 23, 2023
  • Bekki Brown UBC
    Image attribution tooltip
    Permission granted by Bekki Brown
    Image attribution tooltip

    UBC crowns Bekki Brown as its new CEO with a clear mandate to grow

    The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.

    Taren Grom • Jan. 20, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX
    Image attribution tooltip

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    Michael Gibney • Jan. 18, 2023
  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Image attribution tooltip

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

    Taren Grom • Jan. 11, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    Taren Grom • Jan. 9, 2023
  • A person in a white lab coat holds an Ipad and pen and sits across from someone gesturing with their hands.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    To drive trial diversity, one company is bringing them to the patient

    For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

    Karissa Waddick • Dec. 21, 2022
  • arrow change
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

    With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

    Taren Grom • Dec. 9, 2022
  • Charlotte Owens, vice president, head of the Center for Health Equity and Patient Affairs, Takeda
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Takeda’s global quest for health equity

    Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

    Taren Grom • Dec. 8, 2022